Luye Pharma Group Balance Sheet Health
Financial Health criteria checks 4/6
Luye Pharma Group has a total shareholder equity of CN¥14.1B and total debt of CN¥9.4B, which brings its debt-to-equity ratio to 66.6%. Its total assets and total liabilities are CN¥27.2B and CN¥13.1B respectively. Luye Pharma Group's EBIT is CN¥1.3B making its interest coverage ratio 2.9. It has cash and short-term investments of CN¥6.5B.
Key information
66.6%
Debt to equity ratio
CN¥9.39b
Debt
| Interest coverage ratio | 2.9x |
| Cash | CN¥6.48b |
| Equity | CN¥14.08b |
| Total liabilities | CN¥13.11b |
| Total assets | CN¥27.20b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: LYPH.F's short term assets (CN¥12.5B) exceed its short term liabilities (CN¥9.8B).
Long Term Liabilities: LYPH.F's short term assets (CN¥12.5B) exceed its long term liabilities (CN¥3.3B).
Debt to Equity History and Analysis
Debt Level: LYPH.F's net debt to equity ratio (20.6%) is considered satisfactory.
Reducing Debt: LYPH.F's debt to equity ratio has reduced from 70.7% to 66.6% over the past 5 years.
Debt Coverage: LYPH.F's debt is not well covered by operating cash flow (5.4%).
Interest Coverage: LYPH.F's interest payments on its debt are not well covered by EBIT (2.9x coverage).